Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey
1 other identifier
observational
30
1 country
1
Brief Summary
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2016
CompletedFirst Submitted
Initial submission to the registry
April 30, 2019
CompletedFirst Posted
Study publicly available on registry
May 2, 2019
CompletedMay 6, 2019
May 1, 2019
3 months
April 30, 2019
May 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
globe salvage
globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma
2-5 years
Study Arms (2)
group 1
Patients who received intra-arterial chemotherapy as a first line treatment
group 2
Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy
Interventions
Eligibility Criteria
Patients diagnosed with retinoblastoma and who received superselective intra-arterial chemotherapy as a first line treatment or as a salvage treatment after systemic chemotherapy
You may qualify if:
- patients diagnosed with unilateral/bilateral retinoblastoma
You may not qualify if:
- patients with trilateral retinoblastoma
- extraoculer involvement
- patients with blood dyscrasias, bleeding and clotting disorders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istanbul University Cerrahpasa School of Medicine Ophthalmology Department
Istanbul, 34098, Turkey (Türkiye)
Related Publications (1)
Saglam M, Sarici A, Anagnostakou V, Yildiz B, Kocer N, Islak C, Kizilkilic O. An alternative technique of the superselective catheterization of the ophthalmic artery for intra-arterial chemotherapy of the retinoblastoma: retrograde approach through the posterior communicating artery to the ophthalmic artery. Neuroradiology. 2014 Sep;56(9):751-4. doi: 10.1007/s00234-014-1388-1. Epub 2014 Jun 10.
PMID: 24913287BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ophthalmology Specialist, Medical Doctor
Study Record Dates
First Submitted
April 30, 2019
First Posted
May 2, 2019
Study Start
August 30, 2016
Primary Completion
November 30, 2016
Study Completion
November 30, 2016
Last Updated
May 6, 2019
Record last verified: 2019-05
Data Sharing
- IPD Sharing
- Will not share